摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-hydroxy-8-methyl-4'-nitro-isoflavone

中文名称
——
中文别名
——
英文名称
7-hydroxy-8-methyl-4'-nitro-isoflavone
英文别名
IR-206;7-Hydroxy-8-methyl-3-(4-nitrophenyl)-4H-1-benzopyran-4-one;7-hydroxy-8-methyl-3-(4-nitrophenyl)chromen-4-one
7-hydroxy-8-methyl-4'-nitro-isoflavone化学式
CAS
——
化学式
C16H11NO5
mdl
——
分子量
297.267
InChiKey
MMBKDNMPRCZQFQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    22
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    92.4
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    7-hydroxy-8-methyl-4'-nitro-isoflavone 乙醇甲烷对甲苯磺酸一水合物碳酸氢钠乙酸乙酯magnesium sulfate 、 silica gel 作用下, 以 Dioxan ethanol 为溶剂, 反应 30.0h, 以to yield 3,4-dihydro-7-hydroxy-8-methyl-3-(4-aminophenyl)-2H-1-benzopyran, m.p. 150°-151°的产率得到3,4-dihydro-7-hydroxy-8-methyl-3-(4-aminophenyl)-2H-1-benzopyran
    参考文献:
    名称:
    Benzopyrans and use thereof in treating vascular diseases
    摘要:
    式I中的异黄酮##STR1##其中OR,R',R"和环B的基团如规范所定义,表现出有价值的药理特性,特别是用于治疗血管疾病。它们是通过已知的方法制备的。
    公开号:
    US04814346A1
  • 作为产物:
    描述:
    对硝基苯乙腈盐酸三氟化硼乙醚甲基磺酰氯 、 zinc(II) chloride 作用下, 以 乙醚 为溶剂, 反应 2.0h, 生成 7-hydroxy-8-methyl-4'-nitro-isoflavone
    参考文献:
    名称:
    异黄酮和异黄酮作为人类12和15脂氧合酶的强抑制剂的体外研究
    摘要:
    在这项研究中,我们研究了16种异黄酮和异黄酮衍生物作为人类脂氧合酶的潜在抑制剂(血小板12-脂氧合酶,网状细胞15-脂氧合酶-1和上皮15-脂氧合酶-2)。类黄酮黄ical素(一种已知的脂加氧酶抑制剂)用作阳性对照。四种化合物,6,7-二羟基-3'-氯异黄酮(1c),7-羟基-8-甲基-4'-氯异黄酮(5a),7,8-二羟基-4'-甲基异黄酮(5b)和7, 8-dihydroxy-3'methylisoflavan(5c)是有效的12-lipoxygenases和15-lipoxygenase-1的抑制剂,IC 50小于10μm,而6,7-dihydroxy-4-4'-nitroisoflavone(1b)是12-脂氧合酶的选择性抑制剂。对三种最佳抑制剂(1b,5b,5c)进行了对接研究,抗氧化剂测定和动力学测量。结果表明,环A中的邻苯二酚基团对于这些化合物的抗氧化性能至关重要,并且可能对
    DOI:
    10.1111/cbdd.12157
点击查看最新优质反应信息

文献信息

  • <i>In Vitro</i>Study of Isoflavones and Isoflavans as Potent Inhibitors of Human 12- and 15-Lipoxygenases
    作者:Carolina Mascayano、Victoria Espinosa、Silvia Sepúlveda-Boza、Eric K. Hoobler、Steve Perry
    DOI:10.1111/cbdd.12157
    日期:2013.9
    In this study, we have investigated 16 isoflavone and isoflavan derivatives as potential inhibitors of human lipoxygenase (platelet 12‐lipoxygenase, reticulocyte 15lipoxygenase1, and epithelial 15lipoxygenase‐2). The flavonoid baicalein, a known lipoxygenase inhibitor, was used as positive control. Four compounds, 6,7‐dihydroxy‐3′‐chloroisoflavone (1c), 7‐hydroxy‐8‐methyl‐4′‐chloroisoflavan (5a)
    在这项研究中,我们研究了16种异黄酮和异黄酮衍生物作为人类脂氧合酶的潜在抑制剂(血小板12-脂氧合酶,网状细胞15-脂氧合酶-1和上皮15-脂氧合酶-2)。类黄酮黄ical素(一种已知的脂加氧酶抑制剂)用作阳性对照。四种化合物,6,7-二羟基-3'-氯异黄酮(1c),7-羟基-8-甲基-4'-氯异黄酮(5a),7,8-二羟基-4'-甲基异黄酮(5b)和7, 8-dihydroxy-3'methylisoflavan(5c)是有效的12-lipoxygenases和15-lipoxygenase-1的抑制剂,IC 50小于10μm,而6,7-dihydroxy-4-4'-nitroisoflavone(1b)是12-脂氧合酶的选择性抑制剂。对三种最佳抑制剂(1b,5b,5c)进行了对接研究,抗氧化剂测定和动力学测量。结果表明,环A中的邻苯二酚基团对于这些化合物的抗氧化性能至关重要,并且可能对
  • Bicyclic compounds
    申请人:Zyma SA
    公开号:EP0267155A2
    公开(公告)日:1988-05-11
    Isoflavans of the formula I wherein the groups OR, R', R" and ring B are as defined in the specification, exhibit valueable pharmacological properties, especially for the treatment of vascular diseases. They are prepared by methods known per se.
    式 I 的异黄酮(其中基团 OR、R'、R "和环 B 如说明书中所定义)具有宝贵的药理特性,特别是在治疗血管疾病方面。 它们是通过本身已知的方法制备的。
  • US4814346A
    申请人:——
    公开号:US4814346A
    公开(公告)日:1989-03-21
  • Enzymatic Studies of Isoflavonoids as Selective and Potent Inhibitors of Human Leukocyte 5-Lipo-Oxygenase
    作者:Carolina Mascayano、Victoria Espinosa、Silvia Sepúlveda-Boza、Eric K. Hoobler、Steve Perry、Giovanni Diaz、Theodore R. Holman
    DOI:10.1111/cbdd.12469
    日期:2015.7
    Continuing our search to find more potent and selective 5‐LOX inhibitors, we present now the enzymatic evaluation of seventeen isoflavones (IR) and nine isoflavans (HIR), and their in vitro and in cellulo potency against human leukocyte 5‐LOX. Of the 26 compounds tested, 10 isoflavones and 9 isoflavans possessed micromolar potency, but only three were selective against 5‐LOX (IR‐2, HIR‐303, and HIR‐309), with IC50 values at least 10 times lower than those of 12‐LOX, 15‐LOX‐1, and 15‐LOX‐2. Of these three, IR‐2 (6,7‐dihydroxy‐4‐methoxy‐isoflavone, known as texasin) was the most selective 5‐LOX inhibitor, with over 80‐fold potency difference compared with other isozymes; Steered Molecular Dynamics (SMD) studies supported these findings. The presence of the catechol group on ring A (6,7‐dihydroxy versus 7,8‐dihydroxy) correlated with their biological activity, but the reduction of ring C, converting the isoflavones to isoflavans, and the substituent positions on ring B did not affect their potency against 5‐LOX. Two of the most potent/selective inhibitors (HIR‐303 and HIR‐309) were reductive inhibitors and were potent against 5‐LOX in human whole blood, indicating that isoflavans can be potent and selective inhibitors against human leukocyte 5‐LOX in vitro and in cellulo.
  • Benzopyrans and use thereof in treating vascular diseases
    申请人:Zyma SA
    公开号:US04814346A1
    公开(公告)日:1989-03-21
    Isoflavans of the formula I ##STR1## wherein the groups OR, R', R" and ring B are as defined in the specification, exhibit valuable pharmacological properties, especially for the treatment of vascular diseases. They are prepared by methods known per se.
    公式为I ##STR1## 中的异黄酮,其中基团OR、R'、R"和环B的定义如规范中所述,具有有价值的药理特性,特别适用于治疗血管疾病。它们可通过已知的方法制备。
查看更多